induction chemotherapy


Summary: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.

Top Publications

  1. Ke L, Xia W, Qiu W, Huang X, Yang J, Yu Y, et al. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 2017;17:134 pubmed publisher
    ..The objective response rates were 88.1% (95% confidence interval [CI], 0.77 to 0.95) and 100% after induction chemotherapy (ICT) and concurrent chemoradiotherapy (CRT), respectively...
  2. Haldar D, Cockwell P, Richter A, Roberts K, Hirschfield G. An overview of the diagnosis and management of immunoglobulin G4-related disease. CMAJ. 2016;188:953-61 pubmed publisher
  3. Alexander T, Wang L, Inaba H, Triplett B, Pounds S, Ribeiro R, et al. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer. 2017;123:3791-3798 pubmed publisher
    ..Cancer 2017;123:3791-3798. © 2017 American Cancer Society. ..
  4. Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin S. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017;99:407-416 pubmed publisher
    To assess the contribution of induction chemotherapy (IC) before definitive chemoradiation therapy (dCRT) in patients with esophageal cancer (EC) based on recursive partitioning analysis (RPA)...
  5. Panaccione R, Ghosh S, Middleton S, Márquez J, Scott B, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3 pubmed
    ..Combination therapy led to significantly better mucosal healing than azathioprine monotherapy. number, NCT00537316. ..
  6. Jacobus S, Rajkumar S, Weiss M, Stewart A, Stadtmauer E, Callander N, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J. 2016;6:e448 pubmed publisher
  7. Gamis A, Alonzo T, Meshinchi S, Sung L, Gerbing R, Raimondi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021-32 pubmed
    ..09), disease-free survival was better among GO recipients (3 years: 60.6% v. 54.7%; HzR, 0.82; 95% CI, 0.67 to 1.02; P = .07). GO added to chemotherapy improved EFS through a reduction in RR for children and adolescents with AML. ..
  8. Usmani S, Sexton R, Ailawadhi S, Shah J, Valent J, Rosenzweig M, et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334 pubmed publisher
  9. Kishimoto K, Kobayashi R, Hori D, Sano H, Suzuki D, Kobayashi K. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017;37:5845-5849 pubmed
    The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies.

More Information


  1. Deng D, Zhang P, Guo Y, Lim T. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76:1436-1439 pubmed publisher
    ..hUC-MSC has no apparent additional effect over and above standard immunosuppression. NCT01539902; Results. ..
  2. Rouanet P, Rullier E, Lelong B, Maingon P, Tuech J, Pezet D, et al. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial. Dis Colon Rectum. 2017;60:653-663 pubmed publisher
    ..This study aimed to assess the feasibility of radiochemotherapy tailored based on the tumor response to induction chemotherapy (FOLFIRINOX) to obtain a minimum R0 resection rate of 90% in the 4 arms of the study...
  3. Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96:e7151 pubmed publisher
    ..Further large-scale RCTs are needed to verify the treatment effects of ALEM. ..
  4. Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido Laguna I, et al. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer. 2017;123:3816-3824 pubmed publisher
    ..6 months) on multivariate analysis (hazard ratio [HR], 0.80; P < .001). Induction chemotherapy before CRT (HR, 0.67; P < .001) and multiagent chemotherapy (HR, 0.72; P < ...
  5. Gnekow A, Walker D, Kandels D, Picton S, Giorgio Perilongo -, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (?16 years) low grade glioma - A final report. Eur J Cancer. 2017;81:206-225 pubmed publisher
    ..Future trials should use neurological/visual and toxicity outcomes and be designed to discriminate between the impact on disease outcomes of 'duration of therapy' and 'age at stopping therapy'. ..
  6. Shaukat H, O Mara J, Neier M. A Pediatric Case of Persistent Thrombocytopenia in a Patient Who Developed All. J Pediatr Hematol Oncol. 2017;39:e512-e514 pubmed publisher
    ..Our patient was initially diagnosed with immune thrombocytopenic purpura with no evidence of malignancy on bone marrow biopsy but presented shortly after with ALL. ..
  7. Huguet F, Schick U, Pointreau Y. [Role of induction chemotherapy in head and neck cancer: Cons]. Cancer Radiother. 2017;21:510-514 pubmed publisher
    ..A sequential treatment combining induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), followed by (chemo)radiotherapy is frequently used as ..
  8. Mellinghoff S, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97:197-207 pubmed publisher
    ..fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic ..
  9. Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, et al. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica. 2015;100:e99-101 pubmed publisher
  10. Sandborn W, Su C, Sands B, D Haens G, Vermeire S, Schreiber S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723-1736 pubmed publisher
    ..Funded by Pfizer; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain numbers, NCT01465763 , NCT01458951 , and NCT01458574 , respectively.). ..
  11. Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;80:195-202 pubmed publisher
    ..Further investigations are warranted to elucidate the effectiveness of this treatment strategy in future studies. Clinical trials information: UMIN000006332. ..
  12. Baker S. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2015;107: pubmed publisher
    ..Thinking in terms of TOFT can spur new lines of research; examples are given related to the early detection of cancer. ..
  13. Sommat K, Ong W, Hussain A, Soong Y, Tan T, Wee J, et al. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:574-580 pubmed publisher
    ..All patients were treated with IMRT and randomized to induction chemotherapy followed by concurrent chemo-IMRT or concurrent chemo-IMRT alone...
  14. Partanen A, Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Putkonen M, et al. Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. Transfusion. 2017;57:2366-2372 pubmed publisher
    ..Neither cellular composition of the grafts nor post-transplant recovery was affected by the limited pre-transplant exposure to lenalidomide. ..
  15. Chisholm J, Merks J, Casanova M, Bisogno G, Orbach D, Gentet J, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017;83:177-184 pubmed publisher
    ..Eligible patients aged ?6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by ..
  16. Frairia C, Aydin S, Audisio E, Riera L, Aliberti S, Allione B, et al. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. Leuk Res. 2017;61:10-17 pubmed publisher
    ..According to these results, WT1 overexpression might represent an additional MRD tool for risk stratification in patients classified nowadays in CR. ..
  17. Barnes H, See K, BARNETT S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev. 2017;4:CD011917 pubmed publisher
  18. Al Mousa A, Abu Hijlih R, Salem A, Sultan I, Mula Hussain L, Ismael T, et al. Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. J Pediatr Hematol Oncol. 2017;39:e437-e442 pubmed publisher
    ..805; 95% confidence interval, 0.95-24.336). Distant metastases was the predominant site of failure, seen in 5 patients (20%). Omission of methotrexate from the induction chemotherapy regimen did not affect treatment outcome.
  19. Banna G, Parra H, Castaing M, Dieci M, Anile G, Nicolosi M, et al. Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. Anticancer Res. 2017;37:3723-3728 pubmed
    ..5%). The ORR was 46% in 12 (partial responses) out of 26 assessable patients. Histology-based induction combination chemotherapy is active and feasible in elderly patients with stage III NSCLC. ..
  20. Schmaltz H, Borel C, Ciftci S, Takeda Raguin C, Debry C, Schultz P, et al. Induction chemotherapy before surgery for unresectable head and neck cancer. B-ENT. 2016;12:29-32 pubmed
    ..reduce tumour size in patients with locally advanced and/or non-resectable squamous cell carcinoma with induction chemotherapy in order to achieve surgical excision with clear margins and preserve quality of life...
  21. Norsworthy K, Dezern A, Tsai H, Hand W, Varadhan R, Gore S, et al. Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. Leuk Res. 2017;61:25-32 pubmed publisher
    ..6 (95% CI 0.7-3.6), respectively. Our results demonstrate the efficacy and feasibility of TST induction for newly diagnosed patients with AML, with results comparable to that seen in clinical trials with other TST therapies and 7+3. ..
  22. Velu C, Chaubey A, Phelan J, Horman S, Wunderlich M, Guzman M, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014;124:222-36 pubmed publisher
    ..These data establish microRNA as functional effectors of endogenous HOXA9 and HOX-based leukemia oncoproteins, provide a concise in vivo platform to test RNA therapeutics, and suggest therapeutic value for microRNA antagonists in AML. ..
  23. Zhu H, Huang X. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med. 2014;371:2239-41 pubmed publisher
  24. Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J, et al. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017;162:836-845 pubmed publisher
    ..0245) as independent prognostic predictors. Positron emission tomography evaluation of the response of primary and metastatic lesions to induction treatments is important to formulate treatment strategies for cT4 esophageal cancer. ..
  25. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella A, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088 pubmed publisher
    ..These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis. Fondazione Italiana Linfomi. ..
  26. Hurt C, Falk S, Crosby T, McDonald A, Ray R, Joseph G, et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer. 2017;116:1264-1270 pubmed publisher
    ..Nine-month PFS was highly predictive of OS. CAP-CRT remains the superior regimen. SCALOP showed that patients with CA19.9 <46?IU?ml-1 after induction chemotherapy are more likely to benefit from CRT.
  27. Gassner F, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica. 2014;99:67-9 pubmed publisher
  28. Vokes E. Competing roads to larynx preservation. J Clin Oncol. 2013;31:833-5 pubmed publisher
  29. Mateos M, Oriol A, Martinez Lopez J, Teruel A, López de la Guía A, Lopez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood. 2014;124:1887-93 pubmed
    ..Melphalan, plus bortezomib, should be maintained as standard care for the treatment of elderly multiple myeloma patients. This trial was registered at as #NCT00443235. ..
  30. Li J, Zhang W, Kang W, Cao X, Duan M, Zhou D. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leuk Lymphoma. 2012;53:2527-9 pubmed publisher
  31. Chen A, Felix C, Wang P, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18:803-811 pubmed publisher
    ..Patients received two cycles of induction chemotherapy with 175 mg/m2 paclitaxel and carboplatin (target area under the curve of 6) given 21 days ..
  32. Lyman G, Allcott K, Garcia J, Stryker S, Li Y, Reiner M, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017;25:2619-2629 pubmed publisher
    ..Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy. ..
  33. Martin P, Ghione P, Dreyling M. Mantle cell lymphoma - Current standards of care and future directions. Cancer Treat Rev. 2017;58:51-60 pubmed publisher
    ..Indeed, there has never been a time that management of MCL was as complicated while the promise for real improvements in outcomes is so great. ..
  34. Taber D, McGillicuddy J, Bratton C, Rohan V, Nadig S, DuBay D, et al. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017;266:450-456 pubmed publisher
    ..Determine the impact of cytolytic versus IL-2 receptor antibody (IL-2RA) induction on acute rejection, graft loss and death in African-American (AA) kidney transplant (KTX) recipients...
  35. Zhang R, Chen J, Huang H, Ma J, Meng F, Tang Y, et al. Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study. Int J Hematol. 2017;106:221-228 pubmed publisher
    ..8 vs. 7.1%, P < 0.001) and in patients receiving induction chemotherapy than in those receiving consolidation chemotherapy (21.6 vs. 3.7%, P < 0.001)...
  36. Mincham C, Wong G, Teixeira Pinto A, Kennedy S, Alexander S, Larkins N, et al. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients. Transplantation. 2017;101:2146-2151 pubmed publisher
  37. Lee J, Kim H, Joo Y, Lee W, Bae S, Zang D, et al. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2017;35:2754-2763 pubmed publisher
    ..Significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation. ..
  38. Cochrane A, CHEUNG C, Rangan K, Freyer D, Nahata L, Dhall G, et al. Long-term follow-up of endocrine function among young children with newly diagnosed malignant central nervous system tumors treated with irradiation-avoiding regimens. Pediatr Blood Cancer. 2017;64: pubmed publisher
    ..Intensive induction chemotherapy followed by marrow-ablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) without central ..
  39. Pointreau Y, Schick U, Huguet F. [Role and interest of induction chemotherapy for head and neck cancers]. Cancer Radiother. 2017;21:505-509 pubmed publisher
    b>Induction chemotherapy must be integrated in a global approach for locally advanced head and neck cancer. Its use has theoretical advantages but should not compromise locoregional radiotherapy...
  40. Avanzini S, Pio L, Erminio G, Granata C, Holmes K, Gambart M, et al. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017;64: pubmed publisher
    ..In addition, midline perivascular abdominal preoperative IDRF appeared to be predictive not only of surgical outcomes but also of EFS and OS. ..
  41. Sharawat S, Raina V, Kumar L, Sharma A, Bakhshi R, Vishnubhatla S, et al. Quantitative assessment of BAX transcript and flow cytometric expression in acute myeloid leukemia: a prospective study. Hematology. 2014;19:404-11 pubmed publisher
    ..BAX gene expression in AML was evaluated first time with two different methods but did not correlate with the survival outcome. ..
  42. Szychot E, Seunarine K, Mankad K, Thust S, Clark C, Gaze M, et al. Impact of induction chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa on brain volume loss and functional status of children with primitive neuroectodermal tumour. Pediatr Blood Cancer. 2017;64: pubmed publisher
    ..The combination of HART and myeloablative courses of thiotepa is associated with severe neurotoxicity and subsequent decline in performance status in a significant proportion of patients. ..
  43. Sato H, Toyooka S, Soh J, Hotta K, Katsui K, Shien K, et al. Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. Ann Thorac Surg. 2017;104:971-978 pubmed publisher
    ..Our study also indicates that bronchoplasty after induction CRT is feasible in comparison with bronchoplasty in primary surgical procedure. ..
  44. Le T, Kinh N, Cuc N, Tung N, Lam N, Thuy P, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med. 2017;376:2329-2340 pubmed publisher
    ..Funded by the Medical Research Council and others; IVAP Current Controlled Trials number, ISRCTN59144167 .). ..
  45. Mendivil A, Rettenmaier M, Abaid L, Brown J, Mori K, Lopez K, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80:405-410 pubmed publisher
    ..69 ovarian cancer patients who underwent surgery and completed their primary induction chemotherapy were treated with consolidation carboplatin (AUC 10) based HIPEC and compared to a historical cohort that ..
  46. Terry C, Shallis R, Estey E, Lim S. Day 14 bone marrow examination in the management of acute myeloid leukemia. Am J Hematol. 2017;92:1079-1084 pubmed publisher
  47. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas R, Fruchart C, Morschhauser F, et al. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol. 2017;35:2473-2481 pubmed publisher
    ..Conclusion Lenalidomide maintenance for 24 months after obtaining a CR or PR to R-CHOP significantly prolonged PFS in elderly patients with DLBCL. ..
  48. Tufekci O, Yilmaz Bengoa S, Erdem M, Oren H. Induction Failure in Acute Leukemia or Parvovirus B19 Infection?. J Pediatr Hematol Oncol. 2017;39:565 pubmed publisher
  49. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377:1331-1344 pubmed publisher
    ..Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma...
  50. Attal M, Lauwers Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376:1311-1320 pubmed publisher
    ..Supported by Celgene and others; IFM 2009 Study number, NCT01191060 .). ..
  51. Chen Y, Wang Y, Shi Y, Dai G. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients. BMC Cancer. 2017;17:242 pubmed publisher
    ..Findings were much the same for landmark group. In conclusion, timing of CIN is an independent predictor of prognosis in metastatic colon cancer patients received mFOLFOX6, whereas an early-onset of CIN predicts longer survival. ..
  52. Wang C, Tang X, Wang J, Song J, Xu Y. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma. Otolaryngol Head Neck Surg. 2017;157:233-238 pubmed publisher
    Objective This study aimed to compare survival and toxicity between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and concurrent chemoradiotherapy (CCRT) alone in elderly patients with advanced nasopharyngeal ..